Photo

Language
English
Title and Department
Associate Professor
Department of Medicine
Cardiovascular Medicine
Associate Director, Cardiovascular Medicine Fellowship Training Program
Director, Vanderbilt System for EHR-based Research in Cardiovascular Health (V-SERCH)
Professional bio

Quinn S. Wells, MD, PharmD, MSCI, is an Associate Professor of Medicine, Division of Cardiovascular Medicine, at Vanderbilt University Medical Center.

His research program is directed toward precision medicine for cardiovascular disease, with a special interest in cardiomyopathic phenotypes. The overarching goal of his lab is to understand how patient-specific features, including clinical and genetic factors, contribute to variable disease susceptibility and therapeutic response, and then translate this knowledge to patient-centered, precision care.

A major interest is leveraging the power of the electronic health record (EHR), and in 2014 he created and was appointed director of the Vanderbilt System for EHR-based Research in Cardiovascular Health (V-SERCH). V-SERCH is dedicated to developing for conducting research in the EHR environment, including advanced phenotyping methods incorporating machine learning, disease mechanism, and in vivo data.

Dr. Wells' group has led or contributed to multiple cardiovascular genomics efforts including exome sequencing-based Mendelian disease gene discovery, characterization of phenotypic variability in cardiometabolic disease, and studies of cardiovascular and drug toxicity phenotypes that have identified potentially novel risk loci. Methodologically, his group has developed natural language processing (NLP) tools to extract multiple high-value datatypes including ankle-brachial index (ABI) and echocardiographic parameters.

» Email Quinn Wells

 

Key Research Areas

  • Big Data
  • Cardiovascular Imaging
  • Gentics 
  • Heart Failure
  • Multi-omics

Grants

  • 2024-2028 (Industry) Precision Phenotyping for Target Discovery in Cardiorenal Disease. 
  • 2024-2027 (NIH) Leveraging Large-Scale Biobanks to Discover and Define Rare Variant Effects in Hypertrophic Cardiomyopathy 
  • 2023-2026 (NIH) Discovery and Characterization of Rare Variant Effects in Dilated Cardiomyopathy via Large- Scale Biobank Analysis 
  • 2021-2025 (NIH) A Multi-omics evaluation of Carfilzomib-related Cardiotoxicity. 2020-2024. NIH. Vanderbilt Genome-Electronic (VGER) Project
  • 2020-2024 (NIH) Accelerating Research to Advance Care for Adults with Congenital Heart Disease Through Development of Validated Scalable Computational Phenotypes
Education
Graduate
PharmD - Samford University
2002
Medical School
University of Alabama at Birmingham
2006
Internship
Internal Medicine - Massachusetts General Hospital
2009
Residency
Internal Medicine - Massachusetts General Hospital
2009
Fellowship
Co-Chief - CA - Vanderbilt University
2012
Fellowship
Cardiovascular Medicine - Vanderbilt University
2013
Graduate
MSCI - Vanderbilt University
2013
Graduate
MS - Human Genetics/Genetic Epidemiology - Vanderbilt University
2014
Education